ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
نویسندگان
چکیده
aECCO Governing Board; IBD Center, Humanitas Research Hospital, Rozzano, Milan,Italy bDepartment of Biomedical Sciences, Humanitas University, Rozzano, Milan, Italy cGuiCom Member; IBD Center, Humanitas Research Hospital, Rozzano, Milan, Italy dY-ECCO; Department of Medicine, University of Cambridge, Cambridge, UK eCO ClinCom; Department of Gastroenterology, UZ Leuven, Leuven, Belgium fN-ECCO; University of Manchester/Manchester Royal Infirmary, School for Nursing/Gastroenterology, Manchester, UK gP-ECCO; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, Children’s Memorial Health Institute, Warsaw, Poland hECCO EduCom; 1st Department of Medicine, Semmelweis University, Budapest, Hungary iECCO GB; Department of Gastroenterology, Evangelismos Hospital, Athens, Greece jSciCom; Department of Gastroenterology & Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands kECCO Governing Board; University Hospital Clínic de Barcelona, Barcelona, Spain lECCO Governing Board; Gastroenterology and Inserm U954, University Hospital of Nancy, Nancy, France
منابع مشابه
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
Biologics have become key agents for the management of Crohn's disease and ulcerative colitis. Biosimilars are biological medicines similar to previously authorized biologics and are already available in some countries. This ECCO Position Statement defines the collective view of European specialist in inflammatory bowel disease (IBD) concerning biosimilars. Biosimilars are not comparable to gen...
متن کاملThe use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper.
Biological agents are widely used in rheumatology, dermatology and inflammatory bowel disease. Evidence about their efficacy and safety has been strengthened for all those therapeutic indications over the last decade. Biosimilar agents are monoclonal antibodies similar to previously approved biologics. In the European Union, they have been approved for all the indications in the management of i...
متن کاملUse of Biosimilars in Paediatric Inflammatory Bowel Disease: A Position Statement of the ESPGHAN Paediatric IBD Porto Group.
Because the patents for biopharmaceutical monoclonal antibodies have or soon will expire, biosimilars are coming to the market. This will most likely lead to decreased drug costs and so easier access to these expensive agents. Extrapolation, however, of the limited available clinical data from adults with rheumatologic diseases to children with inflammatory bowel disease (IBD) should be done wi...
متن کاملBiosimilars in Crohn's disease.
The patent for some biological medicines used in the treatment of Crohn's disease are close to expire. Biosimilars are biologicals sufficiently similar to a biopharmaceutical already approved by a regulatory agency.1 Several companies are developing biosimilars to tumor necrosis factor and the first biosimilar submitted to the European agency for the treatment of rheumatoid arthritis was develo...
متن کاملUse of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease.
The introduction of biological therapies, particularly anti-TNFα agents, has revolutionized the management of inflammatory bowel disease in those cases which are refractory to conventional treatment; however these drugs are not risk-free and their use has substantially increased the cost of treatment. As marketing protection expires for original, first-generation biopharmaceuticals, lower-cost ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Journal of Crohn's & colitis
دوره 11 1 شماره
صفحات -
تاریخ انتشار 2017